Bristol-Myers Squibb
Company and Pharmaceutical Company
Derrick Z. Jackson: Drug firms dance to same old song on health reform...prices in anticipation of legislation. In an April Wall Street Journal story, Credit Suisse analyst Catherine Arnold detailed how Bristol-Myers Squibb, Pfizer and Eli Lilly raised the prices of leukemia, kidney cancer, attention deficit... In this article: Barack Obama, Credit Suisse, Revenue, Medicare, Leukemia, Cancer, and Rash |
-
Medical News Today | November 22, 2009
Merck KGaA: CHMP Opinion For Erbitux In Advanced Non-Small Cell Lung Cancer
...a wholly-owned subsidiary of Eli Lilly and Company, in 1998. In Japan, ImClone Systems, Bristol-Myers Squibb Company and Merck jointly develop and commercialize Erbitux. Merck has an ongoing commitment to the advancement of oncology...
In this article: Cetuximab, Merck KGaA, Lung cancer, Cancer, Irinotecan, EU, Squamous cell carcinoma, Platinum, and Cilengitide
-
Seeking Alpha | November 15, 2009
Big Pharma Willing to Pay for Biotech Innovation
...exclusive rights to develop and commercialize ALD518 for all potential indications except cancer, for which Alder will retain rights and grant Bristol-Myers Squibb an option to co-develop and commercialize outside the United States.
In this article: Abbott Laboratories, Sanofi-Aventis, Cancer, Astellas, Regeneron, Korea, Japan, Massachusetts, and United States
-
Miami Herald - Breaking News | November 15, 2009
Bristol-Myers splits off Mead Johnson Nutrition
Alder will also receive sales royalties. Meanwhile, Alder gives Bristol-Myers exclusive worldwide rights to develop and sell ALD518 for all potential indications, excluding cancer. S&P SmallCap 600 adds Compellent, Emergent Bio
In this article: Bristol-Myers, YRC Worldwide Inc., Revenue, Rheumatoid arthritis, UPS, and Standard & Poor's
-
San Francisco Chronicle | November 10, 2009
Bristol-Myers signs development deal with Alder
...to develop and sell ALD518 for all potential indications, excluding cancer. Bristol-Myers already sells the drug Orencia as a rheumatoid arthritis treatment. Sales rose 36 percent to $162 million during the third quarter. Advertisers
In this article: Bristol-Myers, Rheumatoid arthritis, NEW YORK, Cancer, and Orencia
-
Xconomy | November 10, 2009
Alder Scores Deal With Bristol-Myers Potentially Worth $1 Billion
...and nationally. The Bothell, WA-based developer of faster and cheaper technology for making antibody drugs has formed a collaboration with Bristol-Myers Squibb, focused on the development of Alder's experimental rheumatoid arthritis drug, that...
In this article: Rheumatoid arthritis, Bristol, Seattle, Cancer, Adalimumab, and Tocilizumab
-
Clearwire Closes $1.5B, Alder Scores $1B Partnership, Software Financings Are Down, & More Seattle-Area Deals News
...as Luke reported today. The company has formed a collaboration with Bristol-Myers Squibb (NYSE: BMY) to develop Alder's experimental rheumatoid arthritis drug, ALD518, and the deal could be worth more than $1 billion. In exchange for granting...
In this article: Clearwire, Seattle, Madrona Venture Group, Roper Industries, Cancer, and NYSE
Trends
Loading...
More on Bristol-Myers Squibb
Description from Wikipedia:
Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical company. Founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were graduates of Hamilton College), Bristol-Myers merged with Squibb Corporation in 1989. James M. Cornelius is the New York City-based company's Chairman and CEO.
Bristol-Myers Squibb manufactures prescription pharmaceuticals in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders. It is also the parent company of Mead Johnson Nutrition, which manufactures nutritional products such as Enfamil baby formulas and infant vitamin supplements like Tri-Vi-Sol. Bristol-Myers Squibb has a mission to "Extend and Enhance Human Life" and works to discover and develop medicines in areas of serious unmet medical need.
BMS' primary R&D sites are located in Lawrenceville, New Jersey (formerly Squibb) and Wallingford, Connecticut (formerly Bristol-Myers), with other sites around the US, in Ireland, and in other countries.
A major restructuring has been implemented which involves focusing on the pharmaceutical business and biologic products along with productivity initiatives, cost-cutting and streamlining business operations.
In 2005, BMS was among 53 entities that contributed the maximum of $250,000 to the second inauguration of President George W. Bush.
BMS is a Fortune 500 Company (#129 in 2007 list).
On July 22, 2009, BMS offered to acquire the biotechnology firm, Medarex, for $16 per share.
- Name:
- Bristol-Myers Squibb Company
- Type:
- Public (NYSE: BMY)
- Location:
- New York, New York
- Founded:
- 1887
- Stock Symbol:
- BMY
- Industry:
- Pharmaceuticals
- Key People:
- James Cornelius, CEO
- Revenue:
- US$ 19.98 billion (2008)
- Net Income:
- US$ 2.165 billion (2008)
- No. of Employees:
- 35,000 (2009)
- Market Cap:
- US$ 36.7 billion (Oct. 2008)
Explore everything named Bristol-Myers Squibb...
